Cytosorbents Corp
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
CTSO$5.83+21.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · · · · | ||||||
| December 31, · · 2023 · · 2022 | ||||||
| · · · | ||||||
| ASSETS · · · | ||||||
| Current Assets: · · · | ||||||
| Cash and cash equivalents | | $14,131,137 | | $22,144,567 | ||
| Grants and accounts receivable, net of allowances of $49,663 and $76,041 at December 31, 2023 and 2022, respectively | | 6,057,072 | | 5,664,941 | ||
| Inventories | | 3,680,129 | | 3,461,586 | ||
| Prepaid expenses and other current assets | | 1,834,485 | | 2,488,597 | ||
| Total current assets | | 25,702,823 | | 33,759,691 | ||
| | | | | | ||
| Property and equipment - net | | 10,056,354 | | 10,743,032 | ||
| Restricted cash | | | 1,483,958 | | | 1,687,459 |
| Right-of-use asset | | | 12,058,896 | | | 12,603,901 |
| Other assets | | 3,958,603 | | 4,437,447 | ||
| Total Assets | | $53,260,634 | | $63,231,530 | ||
| | | | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | ||||
| Current Liabilities: | | | ||||
| Accounts payable | | $3,802,170 | | $1,655,173 | ||
| Accrued expenses and other current liabilities | | 7,870,149 | | 7,950,440 | ||
| Lease liability – current portion | | | 373,636 | | | 108,939 |
| Current maturities of long-term debt | | | 2,500,000 | | | — |
| Total current liabilities | | 14,545,955 | | 9,714,552 | ||
| Lease liability, net of current portion | | | 12,896,659 | | | 13,142,005 |
| Long-term debt, net of current maturities | | 2,542,857 | | 5,000,000 | ||
| Total Liabilities | | 29,985,471 | | 27,856,557 | ||
| | | | ||||
| Commitments and Contingencies (Note 10) | | | | | ||
| Stockholders’ Equity: | | | ||||
| Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022 | | | — | | | — |
| Common Stock, Par Value $0.001, 100,000,000 shares authorized; 54,240,265 and 43,635,715 shares issued and outstanding at December 31, 2023 and 2022, respectively | | 54,240 | | 43,635 | ||
| Additional paid-in capital | | 305,196,874 | | 287,000,021 | ||
| Accumulated other comprehensive income | | 529,321 | | 2,329,195 | ||
| Accumulated deficit | | (282,505,272) | | (253,997,878) | ||
| Total stockholders’ equity | | 23,275,163 | | 35,374,973 | ||
| Total Liabilities and Stockholders’ Equity | | $53,260,634 | | $63,231,530 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.